Ficlatuzumab

Summary

Ficlatuzumab (CHEMBL1743018) is a phase-3 clinical-stage antibody; indicated across 7 conditions including head and neck squamous cell carcinoma and squamous cell carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743018
Name	Ficlatuzumab
Type	Antibody
Max phase	3

Also known as: AV 299, AV-299, Ficlatuzumab, SCH 900105, SCH-900105, FICLATUZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
head and neck squamous cell carcinoma	3	MONDO:0010150	EFO:0000181
squamous cell carcinoma	3	MONDO:0005096	EFO:0000707
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
glioblastoma	1	MONDO:0018177	EFO:0000519
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
plasma cell myeloma	1	MONDO:0009693	EFO:0001378

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE1	7
PHASE2	3
PHASE1/PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06064877	PHASE3	RECRUITING	A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT03013998	PHASE1/PHASE2	RECRUITING	Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT01039948	PHASE1/PHASE2	COMPLETED	A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
NCT02318368	PHASE2	TERMINATED	A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
NCT03422536	PHASE2	COMPLETED	Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT04100330	PHASE2	WITHDRAWN	A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
NCT00725634	PHASE1	COMPLETED	A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
NCT00969410	PHASE1	COMPLETED	A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
NCT01189513	PHASE1	WITHDRAWN	SCH-900105 in Recurrent Glioblastoma
NCT02109627	PHASE1	TERMINATED	Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
NCT02277184	PHASE1	TERMINATED	Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT02277197	PHASE1	COMPLETED	Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT03316599	PHASE1	COMPLETED	Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
NCT02090127	Not specified	NO_LONGER_AVAILABLE	Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).